Ticker

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement…

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy

-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors --

-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 --